Predict your next investment

mulliganbio.com

See what CB Insights has to offer

Investments

11

Portfolio Exits

4

About Mulligan BioCapital

Mulligan BioCapital AG is an investment firm dedicated to the life sciences with a specific Focus on biotechnology with health care applications. We invest in North American and European biotechnology ventures, that promise to transform the healthcare industry as we know it today.

Mulligan BioCapital Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mulligan BioCapital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Mulligan BioCapital in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Mulligan BioCapital Investments

11 Investments

Mulligan BioCapital has made 11 investments. Their latest investment was in 4-Antibody as part of their Series A - II on January 1, 2007.

CBI Logo

Mulligan BioCapital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/15/2007

Series A - II

4-Antibody

$17.6M

No

Advent Life Sciences, BioMedPartners, Grazia Equity, and Life Sciences Partners

1

8/21/2006

Series A

4-Antibody

$6.2M

Yes

BioMedPartners, Grazia Equity, and Life Sciences Partners

1

9/16/2005

Series A

Spinalcord Therapeutics

$15.66M

Yes

BioMedPartners, FNI Venture Capital, Global Life Science Ventures, and Undisclosed Angel Investors

1

4/16/2004

PIPE - III

Subscribe to see more

$99M

Subscribe to see more

10

12/31/2003

Growth Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/15/2007

8/21/2006

9/16/2005

4/16/2004

12/31/2003

Round

Series A - II

Series A

Series A

PIPE - III

Growth Equity

Company

4-Antibody

4-Antibody

Spinalcord Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$17.6M

$6.2M

$15.66M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Advent Life Sciences, BioMedPartners, Grazia Equity, and Life Sciences Partners

BioMedPartners, Grazia Equity, and Life Sciences Partners

BioMedPartners, FNI Venture Capital, Global Life Science Ventures, and Undisclosed Angel Investors

Sources

1

1

1

10

10

Mulligan BioCapital Portfolio Exits

4 Portfolio Exits

Mulligan BioCapital has 4 portfolio exits. Their latest portfolio exit was Spectrum Pharmaceuticals on June 24, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/24/2017

Acq - P2P

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/24/2017

00/00/0000

00/00/0000

00/00/0000

Exit

Acq - P2P

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

Mulligan BioCapital Team

3 Team Members

Mulligan BioCapital has 3 team members, including current Managing Director, Hans Hermann Munchmeyer.

Name

Work History

Title

Status

Hans Hermann Munchmeyer

Managing Director

Current

Jens Klein

Managing Director

Former

Jan Zur Hausen

Deutsche Venture Capital

Managing Director

Former

Name

Hans Hermann Munchmeyer

Jens Klein

Jan Zur Hausen

Work History

Deutsche Venture Capital

Title

Managing Director

Managing Director

Managing Director

Status

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.